About HEPACAM family member 2
HEPACAM family member 2 (HEPACAM2) is a protein
from Homo sapiens identified by UniProt accession
A8MVW5, 462 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | HEPACAM family member 2 |
| UniProt accession | A8MVW5 |
| Gene | HEPACAM2 |
| Organism | Homo sapiens |
| Length | 462 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (48)
Diseases linked to this target (Open Targets).
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- diabetic retinopathy · score 0.09
- Barrett's esophagus · score 0.08
- esophageal adenocarcinoma · score 0.05
- age at menopause · score 0.05
- clear cell renal carcinoma · score 0.04
- breast carcinoma · score 0.04
- metabolite measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A8MVW5-F1 | alphafold | PREDICTED | 78.64 | — |
Amino-acid sequence (462 residues)
MGQDAFMEPF GDTLGVFQCK IYLLLFGACS GLKVTVPSHT VHGVRGQALY LPVHYGFHTP ASDIQIIWLF ERPHTMPKYL LGSVNKSVVP DLEYQHKFTM MPPNASLLIN PLQFPDEGNY IVKVNIQGNG TLSASQKIQV TVDDPVTKPV VQIHPPSGAV EYVGNMTLTC HVEGGTRLAY QWLKNGRPVH TSSTYSFSPQ NNTLHIAPVT KEDIGNYSCL VRNPVSEMES DIIMPIIYYG PYGLQVNSDK GLKVGEVFTV DLGEAILFDC SADSHPPNTY SWIRRTDNTT YIIKHGPRLE VASEKVAQKT MDYVCCAYNN ITGRQDETHF TVIITSVGLE KLAQKGKSLS PLASITGISL FLIISMCLLF LWKKYQPYKV IKQKLEGRPE TEYRKAQTFS GHEDALDDFG IYEFVAFPDV SGVSRIPSRS VPASDCVSGQ DLHSTVYEVI QHIPAQQQDH PE
Explore HEPACAM family member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets